[ Bangkok – February 2nd, 2006 ]
One of the first medicines developed by Drugs for Neglected Diseases initiative (DNDi), fixed-dose artesunate-mefloquine will be easier to use and less expensive than current ACTs, but experts agree that action is needed to make sure the treatments reach patients.
[ Bangkok – February 2nd, 2006 ]
[ December 14, 2005 ]
University of Mississippi , MMV, and DNDi Agree to Collaborate on the Development of Anti-Parasitic Drugs for Both Malaria and Leishmaniasis.
[ Washington , DC – December 11, 2005 ]
First medicines developed by Drugs for Neglected Diseases initiative (DNDi) will be easier to use and less expensive than current ACTs, but action is needed to make sure the treatments reach patients.
[ Delhi, India – October 4, 2005 ]
The Drugs for Neglected Diseases initiative (DNDi), a not-for-profit drug development initiative, is collaborating with the Central Drug Research Institute (CDRI) Lucknow to test their library of compounds for possible activity against parasites that cause deadly neglected diseases such as kala azar and sleeping sickness.
[Marseille, France – September 13, 20051300 CET ]
DNDi presents results of Phase III clinical trials at Marseille conference
[ Tokyo , Japan – July 15, 2005 ]
Today, Drugs for Neglected Diseases initiative (DNDi) signed an agreement to conduct a joint research project with the Kitasato Institute in Japan to find a treatment for human African trypanosomiasis (sleeping sickness), a disease that kills tens of thousands in Africa each year.
[ June 8, 2005 ]
Call to governments to provide significant and sustained support to bring essential new drugs, vaccines, and diagnostics to people suffering and dying from neglected diseases.
[ Paris, April 8, 2005 ]
A collaborative agreement between the DNDi Foundation and Sanofi-Aventis to develop a new, easy-to-use malaria drug at target price below one dollar.
[ Geneva – April 5, 2006 ]
DNDi welcomes the final report of the WHO’s Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH). The report clearly states that it is imperative for governments to set global health priorities and promote innovation to develop and deliver much-needed medicines, vaccines, and diagnostics adapted to the needs of the sick and neglected in developing countries.
[ Geneva, Switzerland – March 2, 2005 ]
For Immediate Release : Africa’s first clinical research facility dedicated to visceral leishmaniasis (VL), was inaugurated by the Drugs for Neglected Diseases initiative (DNDi) on February 9 in the presence of the regional authorities of Ministry of Health, and members from Addis Ababa University (AAU).
[ Geneva , Switzerland – January 20, 2005 ]
The Drugs for Neglected Diseases initiative (DNDi) welcomes the warning issued by the World Health Organization (WHO) to stop selling artemisinin as a monotherapy for malaria, and thus, to prevent the development of resistance to the drug.
[ Geneva – November 22, 2004 ]
DNDi‘s first clinical trial site in Um El Kher, Sudan, is up and running. The first patient started treatment on 17 November 2004. Over the next 6 months, 150 patients are expected to join the trial LEAP 0104 at this site managed by Médecins Sans Frontières (MSF) and led by Dr Manica Balasegaram.
[ Geneva – November 11, 2004 ]
Two important conferences convene this month that will decide the future of patients suffering from neglected diseases in the poorer countries of the world: The Ministerial Summit on Health Research, November 16-20 in Mexico City, and the Dutch Government / WHO “Priority Medicines for the Citizens of Europe and the World” meeting, 18 November in The Hague.
[ Geneva – July 2nd, 2004 ]
Millions of people in developing countries still die from diseases neglected by drug development research. A year after its launch, the Drugs for Neglected Diseases Initiative (DNDi) is starting clinical trials for two fixed-dose drug combinations against malaria, and counts another seven projects in the pipeline for sleeping sickness, visceral leishmaniasis and Chagas disease.
[ Geneva – July 3rd, 2003 ]
A new not-for-profit drug research organization that will harness cutting-edge science to develop medicines for diseases afflicting the world’s poorest people was established today in Geneva. Prestigious health and research institutes from Brazil, France, India, Kenya and Malaysia joined Médecins Sans Frontières to launch the Drugs for Neglected Diseases initiative (DNDi). DNDi will work in close collaboration with the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (WHO/TDR) to achieve its goals.